En español
NIDA

NIDA's Role in Providing Marijuana for Research

Revised June 2015

Under the 1961 international Single Convention on Narcotic Drugs (PDF, 680KB) (amended in 1972), cannabis is designated a Schedule I substance, and participating countries are required to restrict production, manufacture, possession and distribution of marijuana except for medical and scientific purposes. The Drug Enforcement Administration (DEA) regulates the cultivation of marijuana for research purposes through licensing requirements and establishing annual aggregate production quotas under the authority of the 1970 Controlled Substances Act (CSA), which implements the Single Convention. To date, the DEA has only issued a single license for the cultivation of marijuana for research, to the University of Mississippi, which is funded through a NIDA contract. Questions on the authority to issue additional licenses would have to be addressed to the DEA.

NIDA contracts with the University of Mississippi to grow marijuana for use in research studies. The contract was renewed in 2015 under an open solicitation process. The University designates a secure plot of land where marijuana crops are grown every few years, based on current and expected demand. The marijuana is grown, harvested, stored, and made available as bulk marijuana or other purified elements of marijuana to use for research.  For more information on the marijuana farm and current supply: See Information on marijuana farm contract.

Marijuana for use in research can be obtained through the NIDA drug supply program through a process that was updated by the Department of Health and Human Services in June 2015 (PDF, 381KB). Applicants are encouraged to contact the NIDA Drug Supply Program prior to submitting their application to obtain information on availability of the marijuana strain(s) to be requested.  All applicants must fulfill the following requirements:

For NIH Funded Projects (for all studies from basic science to human trials):

  1. Demonstrate scientific validity and ethical soundness through NIH review, consisting of three steps: (1) the NIH peer review system, which assesses the scientific and technical merit of all grant applications; (2) the National Advisory Council of the funding institute, comprising eminent scientists as well as public members; and (3) the funding Institute’s Director, who makes the final decision on the merit of an application for funding, based on peer review, public health significance, and Institute priorities. To find studies approved through this NIH review process, go to http://projectreporter.nih.gov/reporter.cfm (you should use the search terms “marijuana,” “cannabis,” and “cannabinoid”).
  2. An active-status Investigational New Drug (IND) application on file with the FDA (for human research only), which has been evaluated by FDA and found safe to proceed.
  3. A DEA registration for marijuana, a Schedule I controlled substance.

For Non-NIH Funded Human Research Projects:

  1. Demonstrate scientific validity and ethical soundness through review by the Food and Drug Administration (FDA) IND process. Research protocols will undergo a scientific review which assures the safety and rights of subjects and the scientific quality of the clinical investigations, and assesses the likelihood that investigations will yield data capable of meeting the statutory standards for drug marketing approval; and
  2. A DEA registration for marijuana, a Schedule I controlled substance.

When the above steps have been completed, investigators contact the NIDA Drug Supply Program to place an order for marijuana with specific characteristics with regard to concentrations of delta-9-tetrahydro-cannabinol (THC), cannabidiol (CBD), and other cannabinoids. The program official verifies that the application is complete (with all the above-mentioned steps fulfilled), and forwards the order on to the contractor responsible for shipping the marijuana.

For Non-NIH Funded Non-Human/Basic Research Projects: See NIDA Drug Supply Program

Note: While not required in all cases it is recommended that researchers contact the NIDA Drug Supply Program early in the planning of a study to obtain information on specific strains of marijuana available so that this information can be included in the protocol and IND.

This page was last updated June 2015

Get this Publication

    Receive Emerging Trends Articles in your Email!
    You will only receive messages related to Emerging Drug Trends

    Research Report

    Research Report Cover

    Marijuana

    Explores the latest research on marijuana, including the scope of marijuana use in the U.S., health consequences, its effects on every-day activities, available treatments.

    SAMHSA Treatment Locator
    Easy-to-read Drug Facts